CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events Long-Term Durability of Transcatheter Heart Valves: Insights From Bench Testing to 25 Years Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Rationale and design of a randomized clinical trial comparing safety and efficacy of Myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: the LANDMARK trial Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Association Between Functional Impairment and Medication Burden in Adults with Heart Failure Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

Clinical Trial2018 May 19. [Epub ahead of print]

JOURNAL:Cardiovasc Revasc Med. Article Link

Impact of different final optimization techniques on long-term clinical outcomes of left main cross-over stenting

Rigatelli G, Zuin M, Karamfilof K et al. Keywords: Angioplasty; Coronary angiography; Coronary artery disease; Interventional; Surgery

ABSTRACT


BACKGROUND - The optimal final optimization technique to be used in patients after Cross Over Left main stenting remains debatable.


AIM - We evaluate the impact of the post-optimization technique (POT), kissing balloon (KB) and the POT-side-POT techniques on both cardiovascular mortality and event-free survival in patients receiving left main (LM) cross-over stenting for an isolated/distal bifurcation LM disease.

METHODS - Clinical and instrumental records of 128 consecutive patients (102 males, mean age 73.39 ± 9.54 years old) with isolated distal/bifurcation LM disease and bypass surgery contraindications or refusal enrolled to receive LM cross-over stenting between the 1st January 2012 and the 1st January 2017 at two institutions: the Rovigo General Hospital (Rovigo, Italy) and the Alexandrovka Hospital University School of Medicine (Sofia, Bulgaria). Patients has been divided into three groups (POT, KB and POT-side-POT) according the optimal final optimization technique used while the 5-year cardiovascular mortality has been evaluated using the log-rank (Mantel-Cox) analysis.

RESULTS - Baseline angiographic characteristics of the LM disease were mostly equivalent among the three groups. Over a global follow-up of 61.03 ± 0.92 months, the rates of target vessel revascularization, acute myocardial infarction, and stent thrombosis, were not different among groups. Patients treated with POT had a slightly better long-term survival.

CONCLUSIONS - None of these optimization techniques appeared to have clearly better long-term outcomes after LM Cross-over stenting in our retrospective study. POT resulted in a slightly better survival compared to Pot-sid-POT and KB.

Copyright © 2018 Elsevier Inc. All rights reserved.